PRISM BioLab Co. LTD (206A) AI Stock Analysis

• Market Cap: ¥7.31B
• Dividend Yield: N/A
• Average Volume (3M): 2.26M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.92
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: JP
• Employees: 27
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -7.74
• Shares Outstanding: 36,934,000
• 10 Day Avg. Volume: 1,556,930
• 30 Day Avg. Volume: 2,256,993
• PEG Ratio: 0.23
• Price to Book (P/B): 2.27
• Price to Sales (P/S): 9.06
• P/FCF Ratio: -4.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: ¥196.00 ▲(22.50% Upside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is weighed down primarily by weak financial performance—persistent losses and worsening cash flow/funding risk—despite strong recent revenue growth and no debt. Technicals are moderately supportive with a mild positive momentum backdrop, but valuation remains unattractive due to negative earnings and no dividend yield.

Positive Factors

Partnership/licensing business model

A partnership/licensing model aligns PRISM BioLab with pharma partners and converts R&D into contracted revenue streams (upfronts, fees, milestones, royalties). This reduces capital intensity, enables scalable income tied to program progress, and preserves optionality while the pipeline matures.

Debt-free, conservatively financed balance sheet

Having no reported debt provides durable financial flexibility amid negative earnings and cash burn. It lowers solvency risk, preserves borrowing capacity or equity financing optionality, and gives management room to pursue partnerships or R&D without near-term covenant pressure.

Recent sharp revenue growth

Sustained top-line growth across 2024–2025 indicates the company's discovery services or partnered programs are gaining commercial traction. Durable revenue expansion can increase bargaining power on deals, enable reinvestment in core discovery platforms, and form a base for future milestone and royalty income.

Negative Factors

Persistent negative profitability

Deep, multi‑year operating losses show the company has not yet translated revenue growth into sustainable profitability. Persistent negative margins erode shareholder value, limit reinvestment capacity, and increase the probability of dilution or the need for external capital if cost structure isn't corrected.

Deteriorating cash generation / accelerating cash burn

Operating cash flow volatility and expanding free cash flow deficits raise funding risk over the medium term. Continued cash burn forces reliance on partner funding or external financing, which can dilute investors, restrict strategic choices, and pressure timelines for advancing programs.

Negative returns on equity and volatile equity base

Strongly negative ROE and swings in equity indicate the company has struggled to create shareholder value while financing losses. This structural weakness can make future capital raises more expensive, weaken investor confidence, and constrain long-term strategic flexibility if losses persist.

PRISM BioLab Co. LTD Business Overview & Revenue Model

Company Description

PRISM BioLab Co., LTD (206A) is a biotechnology company specializing in the discovery and development of small molecule drugs. The company focuses on innovative structural biology techniques to develop novel therapeutic agents targeting a range of diseases. Its core products include proprietary compounds aimed at addressing unmet medical needs in areas such as oncology and inflammatory diseases.

How the Company Makes Money

PRISM BioLab primarily generates revenue through partnering/licensing arrangements with pharmaceutical and biotechnology companies around its drug discovery capabilities and pipeline programs. Typical revenue sources in this model include (1) upfront payments received when a partner enters a collaboration or obtains rights to a target, program, or platform; (2) research funding or service/technology access fees paid by partners to support discovery and early-stage development work conducted by PRISM BioLab; (3) milestone payments tied to achievement of predefined R&D, clinical, regulatory, or commercial events as partnered programs advance; and (4) royalties (or other commercialization-linked payments) based on sales of any products that reach the market under partner commercialization. If the company develops any programs internally, potential future revenue could also include out-licensing of those assets on similar terms (upfronts/milestones/royalties) or proceeds from a sale/transfer of program rights. Specific figures, partner names, contract terms, and the relative contribution of each stream are null.

PRISM BioLab Co. LTD Financial Statement Overview

Summary

Despite sharp recent revenue growth and a debt-free balance sheet, results are dominated by deeply negative profitability (EBIT/net income) and deteriorating cash generation. Operating cash flow and free cash flow are meaningfully negative in the latest year, increasing funding/execution risk until losses and cash burn stabilize.

Income Statement

Revenue has grown sharply in the last two years (2024 and 2025 annual reports), but profitability remains deeply negative: EBIT and net income are significantly below zero in 2023–2025, implying the company is scaling revenue while operating costs remain very high. Gross margin is still positive but has compressed meaningfully versus 2022, and net margins are heavily negative despite the top-line rebound. Overall, strong growth is outweighed by persistent losses and weak earnings quality.

Balance Sheet

The balance sheet is conservatively financed with no reported debt across all periods, which lowers financial risk and provides flexibility. However, returns on equity are strongly negative in 2023–2025 due to sizable net losses, and equity has been volatile (rising from 2023 to 2024, then declining in 2025), consistent with ongoing cash burn and/or financing dynamics. Strong solvency, but weakened shareholder value creation in recent years.

Cash Flow

Cash generation has deteriorated: operating cash flow turned meaningfully negative in 2023 and again worsened in 2025 after being positive in 2024, and free cash flow is negative in every year except 2022. Free cash flow also declined sharply in 2025 versus 2024, signaling accelerating cash burn. While cash flow can differ from accounting losses, the magnitude and volatility of cash outflows increases funding risk if conditions persist.

Breakdown	Sep 2025	Sep 2024	Sep 2023	Sep 2022
Income Statement
Total Revenue	677.33M	305.62M	112.93M	554.40M
Gross Profit	269.76M	160.54M	80.31M	535.14M
EBITDA	-831.28M	-1.05B	-488.13M	67.89M
Net Income	-833.70M	-1.05B	-526.91M	72.96M
Balance Sheet
Total Assets	3.09B	4.53B	1.21B	1.74B
Cash, Cash Equivalents and Short-Term Investments	2.92B	4.39B	1.13B	1.69B
Total Debt	0.00	0.00	0.00	0.00
Total Liabilities	376.86M	1.03B	63.41M	65.23M
Stockholders Equity	2.71B	3.50B	1.15B	1.67B
Cash Flow
Free Cash Flow	-1.53B	-61.55M	-548.40M	97.25M
Operating Cash Flow	-1.47B	150.14M	-513.81M	102.96M
Investing Cash Flow	-69.01M	-244.19M	-40.38M	-7.87M
Financing Cash Flow	33.59M	3.37B	0.00	110.87M

PRISM BioLab Co. LTD Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 160.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:206A, the sentiment is Positive. The current price of 160 is below the 20-day moving average (MA) of 204.20, below the 50-day MA of 191.92, and below the 200-day MA of 190.10, indicating a bullish trend. The MACD of 2.31 indicates Positive momentum. The RSI at 56.67 is Neutral, neither overbought nor oversold. The STOCH value of 52.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:206A.

PRISM BioLab Co. LTD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4588	55 Neutral	¥80.19B	-17.30	―	―	-9.04%	13.09%
4591	54 Neutral	¥5.38B	-4.17	―	―	-100.00%	7.60%
4594	53 Neutral	¥10.00B	-2.75	―	―	1221.43%	30.54%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
206A	48 Neutral	¥7.31B	-5.04	―	―	―	―
4884	42 Neutral	¥2.89B	-3.45	―	―	-9.77%	-13.86%
4598	39 Underperform	¥3.05B	-3.79	―	―	―	25.25%

PRISM BioLab Co. LTD Corporate Events

PRISM BioLab and Receptor.AI Team Up on AI-Driven Small-Molecule Drug Discovery

PRISM BioLab and Receptor.AI have signed a drug discovery collaboration to build an integrated, AI-navigated, physics-guided platform for designing orally available small molecules against intracellular protein–protein interactions, membrane proteins, and complex receptor systems. The effort combines PRISM’s conformationally rigid PepMetics chemistry with Receptor.AI’s multi-objective AI navigation engine, initially targeting a receptor involved in metabolic disease, including obesity.

Under the agreement, Receptor.AI will use its design algorithms to explore PRISM’s specialized chemical space while both firms jointly seek pharmaceutical partners to apply the combined technologies. Beyond producing clinical candidates, the collaboration is intended to demonstrate the capabilities of this integrated platform, deepen specialized know-how, and position both companies for expanded partnering opportunities in AI-driven small-molecule drug discovery.

The most recent analyst rating on (JP:206A) stock is a Hold with a Yen191.00 price target. To see the full list of analyst forecasts on PRISM BioLab Co. LTD stock, see the JP:206A Stock Forecast page.

PRISM BioLab Widens Quarterly Losses and Withholds Full-Year Guidance

PRISM BioLab reported first-quarter revenue of ¥132 million for the fiscal year ending September 30, 2026, a modest year-on-year increase, but remained in the red with an operating loss of ¥284 million and a net loss of ¥285 million. Earnings per share fell to a loss of ¥7.74, while the company’s equity ratio declined from 87.6% to 80.9%, reflecting a reduction in equity as losses widened.

Total assets decreased slightly to ¥3.0 billion at the end of December 2025, indicating some balance sheet erosion early in the fiscal year. The company maintained its policy of not paying dividends, confirmed a zero-dividend forecast for the current fiscal year, and declined to issue full-year earnings guidance, citing an inability to make a reasonable estimate at this time, which adds uncertainty for investors monitoring its financial trajectory.

The most recent analyst rating on (JP:206A) stock is a Hold with a Yen193.00 price target. To see the full list of analyst forecasts on PRISM BioLab Co. LTD stock, see the JP:206A Stock Forecast page.

PRISM BioLab and Talus Bioscience Collaborate on Novel Drug Discovery

PRISM BioLab and Talus Bioscience have announced a collaboration to discover novel inhibitors for transcription factor and protein-protein interaction targets. By integrating PRISM’s chemistry platform with Talus Bio’s AI-guided regulome profiling, the partnership aims to develop first-in-class therapeutics for previously undruggable targets, potentially revolutionizing drug discovery and offering new treatment avenues for complex diseases.